Pfizer (PFE) Ticks Higher on Expanded Lyrica Indication
Tweet
Share
E-mailGet Alerts PFE Hot Sheet
Join SI Premium – FREE
Pfizer (NYSE: PFE) shares are up early following news its Lyrica caps were approved by the FDA to manage neuropathic pain associated with spinal cord injury.
The stock is up 0.6 percent in early trade.
The stock is up 0.6 percent in early trade.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Pfizer (PFE) to Hold
- FDA: classifies Insulet OmniPod pods recall as Class I due to serious injury risk
- Veraxa Biotech starts cell line development with ATUM for cancer therapy
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
